APA (7th ed.) Citation

X, H., Y, X., Z, W., L, Y., B, Z., F, S., . . . C, W. (2026). Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: An exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing. Molecular cancer, 25(1), . https://doi.org/10.1186/s12943-026-02675-w

Chicago Style (17th ed.) Citation

X, Hu, et al. "Adjuvant Recombinant Human Endostatin Combined with Toripalimab (anti-PD-1) in Locally Advanced Melanoma: An Exploratory Phase 2 Clinical Trial Incorporating Single-cell RNA/TCR/BCR Sequencing." Molecular Cancer 25, no. 1 (2026). https://doi.org/10.1186/s12943-026-02675-w.

MLA (9th ed.) Citation

X, Hu, et al. "Adjuvant Recombinant Human Endostatin Combined with Toripalimab (anti-PD-1) in Locally Advanced Melanoma: An Exploratory Phase 2 Clinical Trial Incorporating Single-cell RNA/TCR/BCR Sequencing." Molecular Cancer, vol. 25, no. 1, 2026, https://doi.org/10.1186/s12943-026-02675-w.